Position statement: Live vaccine use following in utero or lactation infliximab exposure
In March 2022 the European Medicines Agency’s (EMA) published a direct healthcare professional communication (DHPC) regarding the use of live vaccines in infants exposed to infliximab in utero or during breastfeeding. The DHPC stated that live vaccines (e.g. BCG vaccine) should not be given to infants less than 12 months after birth following in utero infliximab exposure, and that administration of a live vaccine should be avoided if a breastfeeding mother is receiving infliximab. ENTIS have issued an official position statement response to the DHPC, click here to read more.